Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA avobenzone 2% minimum in combo sunscreens "arbitrarily imposed" -- Sun Pharma.

This article was originally published in The Tan Sheet

Executive Summary

FDA AVOBENZONE 2% MINIMUM IN COMBO SUNSCREENS "ARBITRARILY IMPOSED," SUN Pharma of Paramus, N.J. argues in Oct. 16 comments on FDA's proposed amendment to the sunscreen tentative final monograph. Published in the Sept. 16 Federal Register, the amendment designates avobenzone a Category I ingredient and allows its use as a "broad spectrum" sunscreen agent alone in concentrations up to 3% and in combination with other Category I ingredients in levels between 2%-3% ("The Tan Sheet" Sept. 23, p. 15). FDA set the 2% minimum level for avobenzone in combination sunscreens to ensure that each ingredient in a combination product contributes to the overall effectiveness.

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS086260

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel